These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35048581)

  • 21. Osteoporosis.
    Compston JE; McClung MR; Leslie WD
    Lancet; 2019 Jan; 393(10169):364-376. PubMed ID: 30696576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on osteoporosis treatment.
    Nogués X; Martinez-Laguna D
    Med Clin (Barc); 2018 Jun; 150(12):479-486. PubMed ID: 29179892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.
    Kendler DL; Chines A; Brandi ML; Papapoulos S; Lewiecki EM; Reginster JY; Muñoz Torres M; Wang A; Bone HG
    Osteoporos Int; 2019 Jan; 30(1):71-78. PubMed ID: 30244369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.
    Lehmann T; Aeberli D
    Osteoporos Int; 2017 Oct; 28(10):3067-3068. PubMed ID: 28589418
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancel the denosumab holiday.
    McClung MR
    Osteoporos Int; 2016 May; 27(5):1677-82. PubMed ID: 26932443
    [No Abstract]   [Full Text] [Related]  

  • 27. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
    Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
    Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
    Anastasilakis AD; Yavropoulou MP; Makras P; Sakellariou GT; Papadopoulou F; Gerou S; Papapoulos SE
    Eur J Endocrinol; 2017 Jun; 176(6):677-683. PubMed ID: 28283537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.
    Bilezikian JP; Lin CJF; Brown JP; Wang AT; Yin X; Ebeling PR; Fahrleitner-Pammer A; Franek E; Gilchrist N; Miller PD; Simon JA; Valter I; Zerbini CAF; Libanati C; Chines A
    Osteoporos Int; 2019 Sep; 30(9):1855-1864. PubMed ID: 31201481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
    Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
    Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anabolic treatment for osteoporosis and fragility fracture risk: one year in review 2024.
    De Mattia G; Maffi M; Mazzantini M
    Clin Exp Rheumatol; 2024 Jul; 42(7):1311-1316. PubMed ID: 39026507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological treatment of osteoporosis in the oldest old.
    Vandenbroucke A; Luyten FP; Flamaing J; Gielen E
    Clin Interv Aging; 2017; 12():1065-1077. PubMed ID: 28740372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
    Ishtiaq S; Fogelman I; Hampson G
    J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab after 8 years.
    Reid IR
    Osteoporos Int; 2015 Dec; 26(12):2759-61. PubMed ID: 26475285
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.
    Palacios S; Kalouche-Khalil L; Rizzoli R; Zapalowski C; Resch H; Adachi JD; Gallagher JC; Feldman RG; Kendler DL; Wang A; Wagman RB; Adami S
    Climacteric; 2015; 18(6):805-12. PubMed ID: 26029985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO.
    Meier C; Uebelhart B; Aubry-Rozier B; Birkhäuser M; Bischoff-Ferrari HA; Frey D; Kressig RW; Lamy O; Lippuner K; Stute P; Suhm N; Ferrari S
    Swiss Med Wkly; 2017; 147():w14484. PubMed ID: 28871570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical vertebral fractures following denosumab discontinuation.
    Polyzos SA; Terpos E
    Endocrine; 2016 Oct; 54(1):271-272. PubMed ID: 27393301
    [No Abstract]   [Full Text] [Related]  

  • 39. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteoporosis in 2017: Addressing the crisis in the treatment of osteoporosis.
    Roux C; Briot K
    Nat Rev Rheumatol; 2018 Feb; 14(2):67-68. PubMed ID: 29323345
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.